Interestingly, agents that block IL-1β activity like IL-1β antibodies and the IL-1 receptor antagonist have been described as improving inflammatory diseases such as T2DM, arthritis, gout, and heart failure [48]. This evidence concerns the gene IL1B and arthritic joint disease.